CP and B-cell chronic lymphocytic leukemia: Although multiple combination therapies for CLL were developed in recent years and some of them were linked with fewer adverse effects such as Bendamustine plus RTX, the standard primary chemotherapy regimen in CLL patients without del(17p) mutation who are aged between 33 and 81 years old still remains to be the combination of Fludarabine, CP, and RTX [68].